Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial

MLA

Simonneau, Gérald, et al. “Predictors of Long-Term Outcomes in Patients Treated with Riociguat for Chronic Thromboembolic Pulmonary Hypertension: Data from the CHEST-2 Open-Label, Randomised, Long-Term Extension Trial.” The Lancet Respiratory Medicine, vol. 4, no. 5, May 2016, pp. 372–80. EBSCOhost, https://doi.org/10.1016/S2213-2600(16)30022-4.

APA

Simonneau, G., D’Armini, A. M., Ghofrani, H.-A., Grimminger, F., Jansa, P., Kim, N. H., Mayer, E., Pulido, T., Wang, C., Colorado, P., Fritsch, A., Meier, C., Nikkho, S., & Hoeper, M. M. (2016). Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. The Lancet Respiratory Medicine, 4(5), 372–380. https://doi.org/10.1016/S2213-2600(16)30022-4

Chicago

Simonneau, Gérald, Andrea M D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Pavel Jansa, Nick H Kim, Eckhard Mayer, et al. 2016. “Predictors of Long-Term Outcomes in Patients Treated with Riociguat for Chronic Thromboembolic Pulmonary Hypertension: Data from the CHEST-2 Open-Label, Randomised, Long-Term Extension Trial.” The Lancet Respiratory Medicine 4 (5): 372–80. doi:10.1016/S2213-2600(16)30022-4.